@trt__np's dismissal of TRT concerns, fact-checked

What did @trt__np actually say?

Vivian, a New Jersey nurse practitioner, told her 111K viewers that if a primary care doctor, cardiologist, endocrinologist, or urologist warns you off testosterone therapy, you should essentially disregard them. Her core argument: "why would you ask them about your testosterone? They're not the experts." She also claims the recent literature from Harvard and PubMed shows how "wonderful" conservative TRT is, and that if your doctor can't cite evidence from the last five years, "he has no idea what he's talking about."

She's recruiting patients via TikTok DM and telemedicine for her New Jersey practice, Elevate Wellness Group. That context matters when evaluating her framing.

Does the science back this up?

Partly. The evidence on TRT has genuinely improved in the last decade, and the most significant recent data does support cautious optimism. But "wonderful" is doing a lot of heavy lifting here.

The TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine), the largest randomized controlled trial on TRT and cardiovascular outcomes to date, found that testosterone replacement in men with hypogonadism and elevated cardiovascular risk was non-inferior to placebo for major adverse cardiac events. That's meaningful. It addressed a longstanding concern that dated back to a halted 2010 trial (Basaria et al., NEJM) that raised red flags about cardiac risk.

However, TRAVERSE also found increased rates of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group. The study authors were careful not to call TRT universally safe. Calling recent literature uniformly positive misrepresents what the data actually shows. It's more accurate to say: the picture is better than it was, and better understood, but not without risk.

What did they get wrong (or right)?

She gets the specialist-knowledge argument mostly right. Most general practitioners receive minimal training in andrology or hormone optimization, and there's documented evidence that many men with symptomatic hypogonadism are undertreated or dismissed. A 2020 review (Ramasamy et al., Therapeutic Advances in Urology) found significant variability in how clinicians interpret testosterone reference ranges, which supports her point that "within range" isn't always the end of the conversation.

But her framing has real problems. Telling patients that doctors outside hormone clinics have no standing to raise safety concerns is genuinely dangerous. A cardiologist warning a patient with a recent arrhythmia about TRT isn't practicing "old bro science," they're doing their job. The blanket dismissal of other specialists, especially the line "it's none of his business anyway," could lead patients to start or continue testosterone while concealing it from their treating physicians. That's a drug interaction and monitoring risk, not an informed choice.

She also implies that conservative TRT is low-risk by default. Dose, formulation, hematocrit monitoring, and individual patient history all change that calculus significantly.

What should you actually know?

TRT is a legitimate treatment for clinically confirmed hypogonadism, defined as low serum testosterone plus symptoms, not just a number on a lab report. The Endocrine Society guidelines (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism) recommend confirming low testosterone on two separate morning measurements before starting therapy.

Ongoing risks that require monitoring include erythrocytosis (elevated hematocrit, which raises clotting risk), suppression of the hypothalamic-pituitary-gonadal axis, reduced sperm production, and potential effects on sleep apnea. These aren't reasons to avoid TRT in appropriate candidates, but they are reasons to maintain open communication with all of your treating providers, not to silo your hormone care away from them.

If your doctor raises concerns about TRT, ask them to be specific. That part of Vivian's advice is reasonable. But "ask for evidence" cuts both ways. Patients should also ask their hormone prescriber for evidence that they have been properly screened, that monitoring is in place, and that the risks specific to their health history have been discussed. Telemedicine TRT practices vary widely in how thorough that intake process actually is.